M

Metagenomi, Inc. Common Stock (MGX)

Healthcare Biotechnology

1.20 $

Closing price · As of: 20. Jul 2026

🔔 Watch stock

Website

Email address First name (optional, for the greeting) New deep dive Scanner moves (enters / drops out) Notify me

Appears in These Scanners

This stock currently matches 7 of our scanner strategies — each hit links to the scanner.

Risk & Weakness

Below the 50- & 200-SMA Near 52-Week Low Stage 4 (Downtrend) Stan Weinstein: Stage 4 Stan Weinstein: Stage 4B- Weakness Cluster

Value & GARP

Benjamin Graham: Net-Nets (⅔ NCAV)

Only genuine hits from verified scanners count; pure ranking metrics (P/E, P/S, and similar, which just sort the whole universe) don't count as a hit. Scanners marked in red are red-flag signals (risk/short scanners) — appearing there is not a seal of approval. View all scanners

Basics

Market Cap The value of the entire company on the market: share price times total shares outstanding.

0.05Mrd. $

Shares Outstanding Total number of shares issued. Price times share count gives market cap.

38Mio.

Float Share of stock freely tradable on the market — not locked up in the hands of founders, insiders, or major shareholders.

67.6%

Beta Volatility versus the overall market: 1 = moves like the market, 2 = twice as much, under 1 = calmer than the market.

0.7

Performance

Perf. 1M Price performance over the last month.

-14.30%

Perf. 3M Price performance over the last 3 months.

-9.10%

Perf. 6M Price performance over the last 6 months.

-31.00%

YTD Performance (%) Price performance since the start of the year (Year to Date).

-23.50%

52-Week-High Distance How far the price sits below its highest point over the last 52 weeks. 0% means the stock is at its year high.

-69.9%

Valuation

P/E Price-to-earnings ratio: how many years of profit does the stock cost? The lower, the cheaper the valuation. No earnings means no P/E.

–

Forward P/E P/E based on expected earnings for the next 12 months instead of past earnings — analysts' bet on the future.

0.0

PEG P/E divided by expected earnings growth: puts valuation in relation to growth. Around 1 is considered fair, well above that is pricey.

–

P/B Price-to-book ratio: market value relative to book equity.

0.3

P/S Price-to-sales ratio: market value divided by annual sales. Important for companies that aren't (yet) profitable.

2.2

EV/EBITDA Enterprise value including debt (EV) relative to operating profit before depreciation and amortization (EBITDA) — more comparable than P/E because debt counts too. Extreme values arise when EBITDA is near zero.

0.0

Price/FCF Market value divided by free cash flow: how many years of freely available cash does the stock cost? More honest than P/E because cash flow is harder to dress up.

–

Profitability

Gross Margin Gross margin: what's left of sales after only direct production costs are deducted — the product's pricing power.

-321.0%

EBIT Margin EBIT margin: operating profit as a percentage of sales — the earning power of the core business before interest and taxes.

–

Net Margin Net margin: what's left of sales as profit after ALL costs, interest, and taxes.

0.0%

Return on Equity Return on equity: how much profit does the company generate per year on shareholders' equity?

-49.0%

Return on Assets Return on assets: how much profit the company generates from its total assets (equity and debt combined).

-23.4%

Balance Sheet & Safety

Equity Ratio Equity ratio: equity as a share of total assets. The higher, the more resilient the balance sheet.

–

Debt/Equity Leverage ratio: financial debt divided by equity. Under 1 is generally seen as solid; negative values mean negative equity.

0.3

warning zone

Altman Z Edward Altman's bankruptcy early-warning score: under 1.8 = danger zone, over 3 = safe. Values well above that mean a very resilient balance sheet.

1.30

Piotroski Balance-sheet health check by Joseph Piotroski: 9 yes/no criteria on profit, cash flow, leverage, and efficiency. 7+ is very solid, under 3 is a red flag.

3 von 9

Growth

Sales Growth Last Quarter Sales growth in the most recently reported quarter versus the same quarter a year ago (YoY).

-69.80%

EPS Growth Last Quarter Growth in earnings per share in the most recently reported quarter versus the same quarter a year ago (YoY).

0.00%

Sales Growth (Year) Sales growth in the last fiscal year versus the year before.

-51.79%

Forward Sales Growth Sales growth analysts expect over the next 12 months — an estimate, not a guarantee.

3.09%

Forward EPS Growth Earnings-per-share growth analysts expect over the next 12 months — an estimate, not a guarantee.

30.30%

Quality & Screener

Stage Weinstein phases 1 through 4: 1 = basing, 2 = uptrend (the only buy phase), 3 = topping, 4 = downtrend. Measured against the 30-week line.

4

RS Rating Relative strength from 1 to 99: an RS of 95 means the stock has outperformed 95% of all stocks.

14

EPS Rating Earnings growth rating from 1 to 99 versus all stocks — high values mean above-average earnings growth.

42

Piotroski Balance-sheet health check by Joseph Piotroski: 9 yes/no criteria on profit, cash flow, leverage, and efficiency. 7+ is very solid, under 3 is a red flag.

3 von 9

Fundamental Rating Our own Fundamental Rating from −100 to +100 with an A+ to F grade: growth, earnings surprises, analyst estimates, margins, cash flow, and balance-sheet safety, all percentile-ranked.

D (-28 von 100)

warning zone

Altman Z Edward Altman's bankruptcy early-warning score: under 1.8 = danger zone, over 3 = safe. Values well above that mean a very resilient balance sheet.

1.30

AI Rating

Uses AI

Metagenomi setzt maschinelles Lernen und Künstliche Intelligenz operativ ein, um die eigenen Genom-Editing-Systeme zu entdecken und zu verbessern; das Geschäftsberichts-Kapitel Item 1 (Business) beschreibt das ausdrücklich als Teil der Entdeckungs- und Entwicklungsplattform. KI ist bei Metagenomi jedoch keine eigene Umsatzquelle - die Firma erzielt bislang ausschließlich Kollaborationsumsatz (kein Produktumsatz) mit genetischen Medikamenten. Damit greift die Kategorie Nutzt KI: dokumentierter operativer Einsatz, aber kein KI-Produkt und keine KI-getriebene Umsatzzeile. Die im Risikoteil genannten KI-Regulierungs-Floskeln (EU AI Act) sind Boilerplate und begründen kein Bedroht.

View the full file — quotes, sources, reviewed filings

„We leverage machine learning and artificial intelligence to enhance our signature gene editing systems."

Wir nutzen maschinelles Lernen und Künstliche Intelligenz, um unsere kennzeichnenden Genom-Editing-Systeme zu verbessern.

„We incorporate artificial intelligence ("AI") solutions into our platform, and these applications may become important in our operations over time."

Wir binden Lösungen der Künstlichen Intelligenz („KI“) in unsere Plattform ein, und diese Anwendungen könnten mit der Zeit für unseren Betrieb wichtig werden.

Filings Reviewed: 10-Q 2026-05-11 · 10-Q 2025-11-12 · 10-Q 2025-08-12 · 10-Q 2025-05-13 · 10-K 2026-03-05 · 10-K 2025-03-17

Rated on July 10, 2026 · How the Rating Is Built

Highlighted are things our editorial team noticed: green = stands out as strong, red = deserves a closer look. No single metric is a verdict on its own — always read it in context.

Quarterly Figures

About the Company

Metagenomi Therapeutics, Inc., ein In-vivo-Genom-Editing-Unternehmen, entwickelt heilende genetische Medizin in den USA.

Employees	118
Headquarters	EmeryVille, CA
Website	metagenomi.co
IPO Date	9. Feb 2024
Next Earnings	11. Aug 2026

Management

Executives per the latest required filings; titles kept in their original language. Source: fundamental data.

Chart

Interactive price chart (TradingView).

Data as of: July 20, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.